In the prostate cancer context, recent studies have demonstrated that SPON2 can promote osteogenic responses via activation of the PI3K–AKT–mTOR pathway, supporting the biological plausibility of this signaling link in prostate tumors (21). The gene discussed is AKT1; the disease is prostate neoplasm.